Authors

Latest:

Dr. Sohal on Eligibility of Patients with Pancreatic Cancer for Clinical Trials

Davendra Sohal, MD, MPH, discusses the SWOG S1505 trial, which looks at initial findings on eligibility and neoadjuvant chemotherapy experience with mFOLFIRINOX versus gemcitabine/nab-paclitaxel for resectable pancreatic adenocarcinoma.

Davendra Sohal, MD, MPH, Cleveland Clinic

David A. Bond, MD

Latest:

Dr. Bond on Second Cancers Following CLL Treatment

David A. Bond, MD, assistant professor, The Ohio State University, discusses the high rates of second cancers in both treatment-naïve and pretreated patients with chronic lymphocytic leukemia who received BTK inhibitors.

David A. Braun, MD, PhD

Latest:

Dr Braun on Future Directions for Research Into Protein Glycosylation in RCC

David A. Braun, MD, PhD, discusses future directions for research into protein glycosylation as a biomarker of response in renal cell carcinoma.

David A. Reardon, MD

Latest:

Will Immunotherapy Become a Standard of Care for Glioblastoma?

Given the current lack of positive phase 3 immunotherapy trials for glioblastoma, a misconception held by oncologists and neuro-oncologists is that immunotherapy has no place in this malignancy.

David Adelstein, MD

Latest:

Dr. Adelstein on Adjuvant Therapy for Oral Cancer

David Adelstein, MD, Department of Hematology and Oncology, Cleveland Clinic, discusses adjuvant therapy options for patients with oral cancer.

David Albala, MD

Latest:

Dr. Albala on the Advantages of PSMA-PET Imaging in Prostate Cancer

David Albala, MD, discusses the key advantages of utilizing PSMA-PET screening in clinical practice for patients with prostate cancer.

David Albala, MD, Crouse Hospital

David Arenberg, MD

Latest:

Dr. Arenberg on Low-Cost Intervention to Improve Tobacco Cessation for Lung Cancer

David Arenberg, MD, associate professor, Department of Internal Medicine at the University of Michigan, discusses preliminary results of a low-cost intervention to improve tobacco cessation practices within a large university health system.

David B. Page, MD

Latest:

Dr. Page on Hormone-Directed Strategies in Triple-Negative Breast Cancer

David B. Page, MD, medical oncologist, Providence Cancer Center, discusses hormone-directed strategies in the treatment of patients with triple-negative breast cancer (TNBC).

David C. Fryefield, MD

Latest:

Developing Alternative Payment Models That Providers and Commercial Payers Support

Although some of the improvement is a result of prevention and screening, advances in technology and in chemotherapy and immunotherapy pharmaceuticals have been major driving forces in the decline in cancer-related death.

David C. Madoff, MD

Latest:

Dr. Madoff on Selecting Patients With HCC Appropriate for Minimally Invasive Therapy

David C. Madoff, MD, professor of Radiology, vice chairman for Academic Affairs at Weill Cornell Medicine, discusses selecting patients with hepatocellular carcinoma who are candidates for minimally invasive therapy.

David C. Metz, MBBCh

Latest:

Dr. Metz Discusses Using a Multidisciplinary Approach When Treating NETs

David C. Metz, MBBCh, professor of medicine, co-director, GI Physiology laboratory, Hospital of the University of Pennsylvania, discusses using a multidisciplinary approach to treating neuroendocrine tumors (NETs).

David C. Metz, MD

Latest:

Dr. Metz on Increasing Incidence of Neuroendocrine Tumors

David C. Metz, MD, gastroenterologist, University of Pennsylvania School of Medicine, associate chief, Medical Affairs, Division of Gastroenterology, discusses the increasing incidence of neuroendocrine tumors.

David C. Portnoy, MD

Latest:

Dr. Portnoy on the Importance of Driver Mutations in the Treatment of NSCLC

David C. Portnoy, MD, medical oncologist and hematologist, West Cancer Center, discusses the importance of driver mutations in the treatment of non–small cell lung cancer (NSCLC).

David Carbone, MD, PhD

Latest:

Dr. Carbone on Pivotal Immunotherapy Studies in Lung Cancer

David Carbone, MD, PhD, director, James Thoracic Center, Ohio State University Comprehensive Cancer Center, discusses two abstracts on immunotherapy that were presented by colleagues at the 2019 World Conference on Lung Cancer in Barcelona, Spain.

David Cella, PhD

Latest:

Dr. Cella on Patient-Reported Outcomes in a Clinical Setting

Dr. David Cella from Northwestern University Feinberg School of Medicine on Patient-Reported Outcomes in a Clinical Setting

David Cibula, MD

Latest:

Dr. Cibula on Adding Dendritic Cell-Based Immunotherapy to Chemotherapy in Ovarian Cancer

David Cibula, MD, a gynecologic oncologist at the Gynaecologic Center of Charles University, discusses a trial that examined the addition of dendritic cell-based immunotherapy to chemotherapy in patients with relapsed ovarian cancer.

David D. Chang, MD, PhD

Latest:

Dr. Chang on the TRINOVA-1 Trial in Ovarian Cancer

David D. Chang, MD, PhD, head of global oncology development at Amgen, discusses the design of the TRINOVA-1 trial in ovarian cancer.

David D. Thiel, MD

Latest:

Dr. Thiel on Protecting Patients and Providers From COVID-19

David D. Thiel, MD, chair, discusses the measures that are being taken to protect patients and providers from the coronavirus disease 2019 (COVID-19).